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Evaluation of the Sensitivity of a pLDH-Based and an Aldolase-Based
Rapid Diagnostic Test for Diagnosis of Uncomplicated and Severe
Malaria Caused by PCR-Confirmed Plasmodium knowlesi, Plasmodium
falciparum, and Plasmodium vivax
Bridget E. Barber,a,b Timothy William,b,c Matthew J. Grigg,a,b Kim Piera,a Tsin W. Yeo,a,d Nicholas M. Ansteya,d
Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australiaa; Infectious Diseases Unit, Queen Elizabeth
Hospital, Kota Kinabalu, Sabah, Malaysiab; Sabah Department of Health, Kota Kinabalu, Sabah, Malaysiac; Royal Darwin Hospital, Darwin, Northern Territory, Australiad
Plasmodium knowlesi can cause severe and fatal humanmalaria in Southeast Asia. Rapid diagnosis of all Plasmodium species is
essential for initiation of effective treatment. Rapid diagnostic tests (RDTs) are sensitive for detection of uncomplicated and se-
vere falciparummalaria but have not been systematically evaluated in knowlesi malaria. At a tertiary referral hospital in Sabah,
Malaysia, we prospectively evaluated the sensitivity of two combination RDTs for the diagnosis of uncomplicated and severe
malaria from all three potentially fatal Plasmodium species, using a pan-Plasmodium lactate dehydrogenase (pLDH)-P. falcipa-
rum histidine-rich protein 2 (PfHRP2) RDT (First Response) and a pan-Plasmodium aldolase-PfHRP2 RDT (ParaHIT). Among
293 hospitalized adults with PCR-confirmed Plasmodiummonoinfection, the sensitivity of the pLDH component of the pLDH-
PfHRP2 RDTwas 74% (95/129; 95% confidence interval [CI], 65 to 80%), 91% (110/121; 95% CI, 84 to 95%), and 95% (41/43;
95% CI, 85 to 99%) for PCR-confirmed P. knowlesi, P. falciparum, and P. vivax infections, respectively, and 88% (30/34; 95% CI,
73 to 95%), 90% (38/42; 95% CI, 78 to 96%), and 100% (12/12; 95% CI, 76 to 100%) among patients tested before antimalarial
treatment was begun. Sensitivity in severe malaria was 95% (36/38; 95% CI, 83 to 99), 100% (13/13; 95% CI, 77 to 100), and 100%
(7/7; 95% CI, 65 to 100%), respectively. The aldolase component of the aldolase-PfHRP2 RDT performed poorly in all Plasmo-
dium species. The pLDH-based RDT was highly sensitive for the diagnosis of severe malaria from all species; however, neither
the pLDH- nor aldolase-based RDT demonstrated sufficiently high overall sensitivity for P. knowlesi. More sensitive RDTs are
needed in regions of P. knowlesi endemicity.
The simian parasite Plasmodium knowlesi is a common cause ofhuman malaria in all age groups in Malaysian Borneo (1–5). In
Sabah, Malaysia, the incidence of knowlesi malaria has increased
with the control of Plasmodium falciparum and Plasmodium vivax
(6) and accounts for up to 80% of malaria admissions to district
hospitals (1, 3–5). The geographic range of P. knowlesi corre-
sponds to the overlapping distribution of the simian hosts and the
forest-dwelling Anopheles leucosphyrus group of mosquitoes and
extends across all of Southeast Asia from southern China, Taiwan,
Philippines, and Indonesia to Bangladesh and eastern India. Hu-
man P. knowlesi infection has been reported in many of these
countries and in travelers returning to regions where the parasite
is not endemic (7, 8). The 24-h replication cycle of P. knowlesimay
be associated with rapidly increasing parasite counts with conse-
quent complications and fatality rates comparable to those of P.
falciparum (9, 10). However, risk of death appears to be low with
early initiation of intravenous artesunate and oral artemisinin
combination therapy for severe and nonsevere disease, respec-
tively (9, 11). Prompt diagnosis of P. knowlesi infection is there-
fore essential to allow early commencement of effective treatment.
In Malaysia and much of Southeast Asia, P. knowlesi is coen-
demic with the two major human Plasmodium species, P. falcipa-
rum and P. vivax. The diagnosis of malaria relies primarily on
microscopic examination of stained blood smears. However, mi-
croscopy is associated with several limitations, including the need
for well-trained staff and appropriately maintained microscopes.
Maintaining high skill levels among microscopists can be partic-
ularly difficult in areas of low malaria transmission. Rapid diag-
nostic tests (RDTs) provide an alternative method of detection
which can be performed by staff with minimal training and are
now widely used in many areas of malaria endemicity. The anti-
gens detected by RDTs include P. falciparum-specific histidine-
rich protein 2 (PfHRP2), genus-specific aldolase (pan-aldolase),
and pan-Plasmodium lactate dehydrogenase (pan-pLDH) (12), as
well as P. vivax-specific (13, 14) and P. falciparum-specific (15)
pLDH. Limited data from case reports demonstrate that RDTs
detecting pan-aldolase and pan-pLDH may be used to detect P.
knowlesi (16–20); however, the sensitivity of any RDT for the di-
agnosis of P. knowlesi has not been evaluated.
Data on the sensitivity of RDTs in the diagnosis of severe ma-
laria from any Plasmodium species are also limited. Only four
studies have evaluated the use of PfHRP2-based RDTs in severe
falciparum malaria (21–24), with one of these also reporting on
the use of a pLDH-based RDT (21) and another reporting on the
use of an aldolase-based RDT (24). Importantly, there are no data
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on the sensitivity of the best available RDTs in the diagnosis of
severe malaria from the other two major causes of severe malaria
in Asia, P. knowlesi and P. vivax. The latter species, previously
thought to be benign, is now recognized as a cause of severe and
fatal malaria in areas of endemicity, particularly in the presence of
comorbidities (25, 26). Determining the sensitivity of RDTs in
severe malaria from any Plasmodium species is important as a
false-negative result may lead to delayed or inappropriate treat-
ment with consequent death.
We prospectively evaluated the sensitivity of a pan-pLDH-
PfHRP2 RDT and a pan-aldolase-PfHRP2 RDT for the diagnosis
of severe and nonsevere knowlesi, falciparum, and vivax malaria at
a tertiary referral hospital. We chose the best-performing pan-
pLDH and pan-aldolase RDTs, respectively, from the WHO RDT
product testing rounds 1 and 2 that were commercially available at
the time of the study (27).
MATERIALS AND METHODS
Study site and referral system. This study was conducted at Queen Eliz-
abeth Hospital (QEH), an adult tertiary referral hospital in Kota Kinabalu,
Sabah, Malaysia. The hospital services the West Coast and Kudat Divi-
sions of Sabah, with six district hospitals and a population of 1.14 million.
From mid-2010, in response to ongoing malaria deaths in Sabah (9, 10),
new guidelines were implemented, including tertiary hospital referral for
all malaria patients with a thick blood film reported as 4 (indicating10
parasites/high-power microscopy field) or with any evidence of severe
malaria. Treatment was commenced pretransfer, and a pretreatment
blood film was sent with the patient. Local health clinics within the Kota
Kinabalu area were required to refer all malaria patients to QEH for ad-
mission, with treatment commencing on arrival.
Subjects. All patients admitted to QEH with a microscopic diagnosis
of malaria were assessed for eligibility from September 2010 to October
2011 as part of a prospective study of the epidemiology, clinical spectrum,
and pathophysiology of knowlesi malaria, reported separately (11). Non-
pregnant patients of12 years old were enrolled if they were within 18 h
of commencing malaria treatment (with 18 h chosen for both pathophys-
iological and logistical purposes), had no major comorbidities, and had
not previously been enrolled in the study. Patients who had mixed species
infection (n  16) or were PCR negative were retrospectively excluded.
Patients were classified as having severe malaria using modified 2010
WHO severe malaria criteria (11, 28, 29). Written informed consent was
provided by patients or their relatives. Approvals were obtained from the
Ethics Committees of the Malaysian Ministry of Health and Menzies
School of Health Research.
RDT selection. WHO RDT product testing performance results from
rounds 1 and 2 were used to identify the RDTs with the highest reported
sensitivities for both P. falciparum and P. vivax (27). We then selected the
pan-pLDH and pan-aldolase RDT with the highest reported sensitivities
(27) that could be sourced commercially at the time of study: the First
Response Malaria Antigen pLDH/HRP2 Combo Card Test (First Re-
sponse; Premier Medical Corporation Ltd., Mumbai, India), which de-
tects pan-pLDH and PfHRP2, and the ParaHIT Total Dipstick (ParaHIT;
SPAN Diagnostics, Ltd., Surat, India), which detects pan-aldolase and
PfHRP2.
The panel detection scores (PDSs; a composite index of test positivity
as well as of intertest and interlot consistency in performance [30]) for the
First Response RDT were 84% and 100% for detection of P. falciparum at
low (200 parasites/l) and high (2,000 to 5,000 parasites/l) densities,
respectively, and 75% and 100% for the detection of P. vivax at low and
high densities, respectively. For the ParaHIT RDT, the PDSs at low and
high densities were 64% and 99%, respectively, for detection of P. falcip-
arum and 10% and 98%, respectively, for the detection of P. vivax.
Study procedures. Standardized data forms were used to record de-
mographic and clinical information. Venous blood was collected in a
labeled tube containing citrate, theophylline, adenosine, and dipyridam-
ole (CTAD), and thick and thin blood smears were prepared. RDTs were
performed on enrolment according to the manufacturers’ instructions,
and results were recorded by one of two research laboratory technicians
unaware of the microscopy result. Results were recorded as follows: neg-
ative, no clearly visible band; 1, faint band; 2, a band darker than 1 but
lighter than that of the control; 3, same as the control band; 4, a band
darker than the control. Results were cross-checked regularly by the study
clinician to ensure consistent reporting between laboratory technicians.
The ParaHIT RDT was unavailable for a 4-week period during April to
May 2011, with its use then discontinued in September 2011.
Blood smear examination was performed by microscopists at referring
district hospitals or at QEH, with slides later cross-checked by an experi-
enced research microscopist. Parasite density was quantified by the re-
search microscopist using pretreatment slides and reported as parasites
per 200 leukocytes or per 1,000 erythrocytes and converted to the number
of parasites/l using the patient’s leukocyte count or hematocrit, respec-
tively. Where pretreatment slides were unavailable (6%), referring hospi-
tal microscopy was used, and the grades 1 to 4 were converted into
numbers of parasites/l using the relevant median parasite density. Par-
asite DNA was extracted and PCR was performed as reported previously
(11), using previously described methods for P. falciparum, P. vivax, Plas-
modium ovale, and Plasmodiummalariae (31), and P. knowlesi (32) detec-
tion.
Statistical analysis. Data were analyzed using STATA, version 10.1
(StataCorp LP, College Station, TX). Intergroup differences were com-
pared using a Kruskal-Wallis test for nonnormally distributed continuous
variables, and a 2 test was used for categorical variables. The sensitivity of
RDTs for each species was defined as the total number of positive results
divided by the total number of samples positive for that species by PCR;
95% confidence intervals (CIs) were estimated using Wilson’s method.
Spearman’s correlation coefficient was used to assess the association be-
tween parasite count and intensity of the RDT band.
RESULTS
Baseline demographics and clinical features. From September
2010 to October 2011, 293 patients had pan-pLDH-PfHRP2 with
or without aldolase-PfHRP2 RDTs performed, including 129 pa-
tients withP. knowlesi, 121 withP. falciparum, and 43 withP. vivax
infections. Baseline demographics, reported previously (11), are
shown in Table 1. Patients with knowlesi malaria were signifi-
cantly older than those with falciparum or vivax malaria, with a
median age of 46 years versus 27 and 24 years, respectively (P 
0.001). The majority (73%) of patients were male, and this did not
differ between infecting species. Most patients (66%) with
knowlesi malaria were referred from district hospitals, and 74%
had commenced antimalarial treatment prior to enrolment in the
study. The median time from commencing treatment to enrol-
ment for patients with knowlesi malaria was 5.1 h (range, 0 to
18 h). Severe malaria occurred in 38/129 (29%) patients with P.
knowlesi, 13/121 (11%) with P. falciparum, and 7/43 (16%) with P.
vivax infections (Table 1).
Pan-pLDH-PfHRP2 (First Response) RDT. Results of the
pLDH component of the First Response RDT are shown in Fig. 1
and 2 and in Table S1 in the supplemental material. Among all
patients with knowlesi malaria, 95/129 had positive results, giving
a sensitivity of 74% (95% CI, 65 to 80%). The sensitivity of the test
was higher when only pretreatment samples were analyzed, with
30/34 positive results (sensitivity, 88% [95% CI, 73 to 95%]) (see
Table S1). The four patients with pretreatment samples and
negative pLDH results had parasite counts of 75, 282, 320, and
11,078 parasites/l. The lowest parasite count among patients
RDTs for Diagnosis of Knowlesi Malaria
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with pretreatment samples and a positive pLDH result was 907
parasites/l.
The sensitivity of the pLDH test for knowlesi malaria increased
with increasing parasite count (Fig. 2). Among patients enrolled
prior to treatment and with parasite counts of 1,000 parasites/
l, sensitivity was 97% (95% CI, 83 to 99%), but it was only 25%
among patients with parasite counts of 1,000 parasites/l.
Among the 38 patients with severe knowlesi malaria, 36 had a
positive result (sensitivity of 95% [95% CI, 83 to 99%]); 31 (82%)
TABLE 1 Baseline demographic and clinical features
Parameter
Value by infecting organisma
P valueP. knowlesi (n 129) P. falciparum (n 121) P. vivax (n 43)
Age (yr)
Median (IQR) 46 (29–58) 27 (17–40) 24 (18–42) <0.001
Range 14–83 13–78 13–79
No. of males (%) 96 (74) 87 (71) 33 (77) 0.769
Source of referral (no. of patients [%]) <0.001
QEH or local health clinic 44 (34) 75 (61) 22 (51)
District Hospital 86 (66) 47 (39) 21 (49)
No. of patients (%) enrolled
pretreatment
34 (26) 42 (34) 12 (28) 0.231
Median time on malaria treatment
(h [IQR])
5.13 (0–11.47) 4.04 (0–11.69) 4.81 (0–9.68) 0.726
No. of patients (%) with severe
malaria
38 (29%) 13 (11%) 7 (46%) <0.001
Median parasite density count/l
(IQR [range])
All patients 8,537 (1,980–35,495 [32–584,015]) 11,610 (4,387–36,977 [16–959,383]) 4,938 (2,848–12,927 [72–84,403]) 0.009
Nonsevere malaria 4,841 (1,581–14,994 [65–62,360]) 10,937 (4,002–32,326 [16–218,921]) 4,753 (2,369–10,316 [72–46,849]) <0.001
Severe malaria 80,359 (25,874–168,279 [32–584,015]) 72,270 (27,905–273,909 [625–959,383]) 10,243 (4,387–40,895 [460–84,403]) 0.070
Severity criteria among patients with
severe malaria
Median no. of criteria (range) 2 (1–6) 3 (1–4) 1 (1–2) 0.039
No. of patients (%) with:
Hyperparasitemia 18 (47) 2 (15) 0
Respiratory distress 14 (37) 4 (31) 1 (14)
Hypotension 13 (34) 6 (49) 3 (43)
Jaundice 20 (53) 9 (69) 2 (29)
Acute kidney injury 9 (24) 3 (23) 0
Metabolic acidosis 4 (11) 4 (31) 0
Severe anemia 2 (5) 2 (15) 0
Abnormal bleeding 2 (5) 1 (8) 1 (14)
Multiple convulsions 0 0 1 (14)
Coma 0 0 0
a Table includes data previously reported (11).
bBoldface indicates significant values.
FIG 1 Parasite count by pLDH-band intensity for all samples. Horizontal
lines indicate medians; boxes indicate interquartile ranges; vertical lines indi-
cate ranges. Among patients with P. knowlesi infection, the pLDH band was
negative in 34 (26%), 1 in 34 (26%), 2 in 17 (13%), 3 in 17 (13%), 4 in
24 (18%), and recorded only as positive in 3 (2%). Among patients with P.
falciparum infection, the pLDH band was negative in 11 (9%), 1 in 35 (29%),
2 in 17 (14%), 3 in 24 (20%), 4 in 30 (25%), and recorded as positive in
4 (3%). Among patients with P. vivax infection, the pLDH band was negative
in 2 (5%), 1 in 4 (9%), 2 in 5 (12%), 3 in 7 (16%), 4 in 20 (47%), and
recorded as positive in 5 (12%).
FIG 2 Sensitivity of the pLDH-component of the First Response RDT by
parasite count. Wide horizontal bars indicate sensitivity. Vertical lines repre-
sent 95% confidence intervals. Among patients with P. knowlesi infection, 18
(14%) had103 parasites/l, 52 (40%) had 103 to104 parasites/l, 41 (32%)
had 104 to 105 parasites/l, and 18 (14%) had 105 parasites/l. Among
patients with P. falciparum infection, 10 (8%) had103 parasites/l, 42 (35%)
had 103 to 104 parasites/l, 60 (50%) had 104 to 105 parasites/l, and 9
(7%) had105 parasites/l. Among patients with P. vivax infection, 8 (19%)
had103 parasites/l, 21 (49%) had 103 to104 parasites/l, and 14 (33%)
had 104 to105 parasites/l.
Barber et al.
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of these patients had commenced malaria treatment a median of
5.7 h prior to enrolment. The two patients with severe knowlesi
malaria and negative results had parasite counts of 3,486 and
48,833 parasites/l and were enrolled 13 and 9 h, respectively,
after treatment.
The sensitivity of the pLDH test for P. falciparum was 91%
(95% CI, 84 to 95%) and was not affected by the inclusion of
posttreatment samples. Sensitivity of the test decreased at parasite
counts of 1,000 parasites/l, with only 6/10 (60%) positive re-
sults, compared to 104/111 (94%) among patients with parasite
counts of1,000 parasites/l. The lowest parasite count detected
was 16 parasites/l; however, parasitemia ranged from 234 to
25,308 (median, 1,698) parasites/l among the 11 patients with
negative results. The sensitivity of the pLDH test among patients
with severe falciparum malaria was 100% (95% CI, 77 to 100%),
with nine (69%) patients having already commenced malaria
treatment a median of 3.8 h prior to enrolment.
The sensitivity of the pLDH test for vivax malaria was 95%
(95% CI, 85 to 99%) when all samples were included and 100%
(95% CI, 76 to 100) among the 12 pretreatment samples, which
included a parasitemia of 72 parasites/l. The sensitivity of the
pLDH test among the seven patients with severe vivax malaria was
100% (95% CI, 65 to 100%); six of these patients commenced
treatment a median 9.2 h prior to enrolment.
The intensity of the pLDH band (grades 1 to 4) was a good
indicator of parasitemia among patients with knowlesi malaria,
with the median parasite count increasing with each successive
grade (Spearman’s correlation coefficient, 0.61; P  0.0001) (see
Table S2 in the supplemental material). Patients with knowlesi
malaria and a 4 pLDH band also had a 7.3-fold (95% CI, 2.3- to
24-fold) higher risk of severe disease (defined using modified 2010
WHO criteria [11]) than those with pLDH bands with intensities
of 1 to 3 (P 0.0001). Among these patients 17/24 (71%) had
severe malaria, compared to 17/68 (25%) patients with knowlesi
malaria and pLDH bands graded 1 to 3 (Table 2). The risk of
severity increased further among patients of 50 years old with
knowlesi malaria and a band intensity of 4, of whom 11/13
(85%) had severe disease. The median intensity score of the pLDH
band was 4 (interquartile range [IQR], 2 to 4) among all
patients with severe knowlesi malaria, compared to a grade of 1
(IQR, 0 to 3) among patients with nonsevere knowlesi malaria
(P  0.0001). This difference was less marked among patients
with severe and nonsevere falciparum malaria (median intensity
scores of 4 [IQR, 2 to 4] and 2 [IQR, 1 to 4], respectively; P 
0.007) and among patients with severe and nonsevere vivax ma-
laria (median intensity scores of 4 [IQR, 3 to 4] and 4 [IQR, 2.5 to
4], respectively; P 0.360).
The sensitivity of the First Response PfHRP2 RDT for falcipa-
rum malaria was 98% overall and 100% among those with severe
disease. The two patients with false-negative results were enrolled
15 and 17 h after commencing antimalarial treatment and had
pretreatment parasite counts of 10,098 and 101,686 parasites/l.
No patient with knowlesi or vivax malaria had a positive HRP2
result.
Pan-aldolase-PfHRP2 (ParaHIT) RDT. The sensitivity of the
aldolase component of the ParaHIT RDT was low for all species
(see Table S2 in the supplemental material). Only 22/96 (23%),
37/84 (44%), and 20/36 (56%) patients with P. knowlesi, P. falcip-
arum, and P. vivax infections, respectively, had positive aldolase
results, with similar results obtained when posttreatment samples
were excluded (sensitivities of 27%, 50%, and 73% for P. knowlesi,
P. falciparum, and P. vivax, respectively). The sensitivity of the
aldolase test among patients with severe malaria was 39% (95%
CI, 24 to 56%), 50% (95% CI, 22 to 78%) and 83% (95% CI, 44 to
97%) for patients with P. knowlesi (n 31), P. falciparum (n 8),
and P. vivax (n  6) infections, respectively. Sensitivity was low
even among patients with higher parasite counts. Among patients
with pretreatment samples and parasite counts of10,000 parasites/
l, only 5/11 (45%) and 10/19 (56%) of those withP. knowlesi andP.
falciparum infections, respectively, had positive results.
Among patients with P. falciparum infection, 79/84 (94%) had
a positive PfHRP2 result, including all eight patients with severe
malaria. Four of the five patients with nonsevere malaria and false-
negative results were enrolled 4 to 16 h after treatment, with pre-
treatment parasite counts of 444 to 15,503 parasites/l, while one
patient was enrolled pretreatment with a parasitemia of 3,990 par-
asites/l. One patient with P. knowlesi and two with P. vivax in-
fections had false-positive ParaHIT PfHRP2 results.
DISCUSSION
This is the first study to systematically evaluate the sensitivities of
RDTs for the diagnosis of knowlesi malaria and the first to evalu-
ate the sensitivities of the best available RDTs for the diagnosis of
nonfalciparum severe malaria. The pLDH-based RDT performed
better than the aldolase-based RDT for the diagnosis of knowlesi
malaria of any severity and demonstrated good sensitivity at par-
asite counts of 1,000 parasites/l. This RDT performed well
among patients with severe knowlesi malaria, among whom sensitiv-
ity was 95%. Sensitivity was poor, however, at low parasite counts.
Given thatP. knowlesi is associated with lower parasite counts thanP.
falciparum among patients with nonsevere malaria (11), that the par-
asite has a rapid replication cycle and is associated with relatively high
rates of severe disease (11), and that late diagnosis has been associated
with fatal outcomes (33), the poor sensitivity at low parasite counts of
both pLDH- and aldolase-based RDTs limits their utility in areas of
knowlesi malaria endemicity.
Despite the suboptimal sensitivity of the pLDH-based test in
knowlesi malaria, we found that the intensity of the pLDH band
correlated well with P. knowlesi parasitemia and risk of severe
disease. In particular, a 4 band was associated with an increased
risk of complications, particularly in older patients who are at
greater risk of severe disease (2, 9, 11). P. knowlesi parasite counts
are strongly associated with complications, with the risk of severe
disease increasing 11-fold and 28-fold with parasite counts of
20,000 parasites/l and 100,000 parasites/l, respectively
(11). Despite this, in Sabah, malaria slides are often reported only
on a scale of 1 to 4, with slides with 10 parasites per high-
TABLE 2 Risk of severe malaria by intensity of First Response pLDH
band
Infecting
organism
No. of severe
malaria patients (%)
by pLDH band
intensity
Odds ratio (95%
CI) P value4 1–3
P. knowlesi 17 (71) 17 (25) 7.29 (2.33–24.01) 0.0001
P. falciparum 8 (27) 5 (6.7) 5.16 (1.31–22.85) 0.005
P. vivax 4 (20) 2 (13) 1.75 (0.21–21.81) 0.549
RDTs for Diagnosis of Knowlesi Malaria
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power microscopy field (or approximately 4,000 parasites/l) re-
ported only as 4. Consequently, hyperparasitemia, with its asso-
ciated risk of complications, may be underrecognized by
clinicians, potentially leading to undertreatment and monitoring.
Use of a pLDH-based RDT may assist clinicians to recognize pa-
tients at high risk of severe disease in settings where parasite
counts are unavailable.
The pLDH-based RDT performed well for P. vivax, with an
overall sensitivity of 95% and sensitivity of 100% among those
with severe disease. False-negative results occurred in only two
patients, both of whom had already commenced antimalarial
treatment. This finding confirms another recent report of the ex-
cellent sensitivity of the First Response RDT for detecting P. vivax
(34). In our study this RDT also performed well for P. falciparum;
the sensitivity of the HRP2 component of the test was 98% overall
and 100% among patients with severe disease. This provides con-
firmation from Southeast Asia of recent reports of the very high
sensitivity of HRP2-based RDTs in severe falciparum malaria in
Africa (21, 23) and India (22), despite the potential for geographic
genetic variability in PfHRP2 (34–37).
The aldolase component of the aldolase-based RDT performed
poorly for all species, with a sensitivity of50% for knowlesi and
falciparum malaria. Sensitivity was poor even at higher parasite
densities, and less than half of patients with severe knowlesi ma-
laria recorded a positive result. Using an aldolase-based RDT with
poorer performance characteristics on WHO product testing, a
recent study also reported poor sensitivity for the diagnosis of
severe vivax malaria (24). The similarly poor performance of al-
dolase-based RDTs has also been reported in uncomplicated ma-
laria (38, 39). Taking these results together, the use of aldolase-
based RDTs for diagnosis of nonfalciparum species of any severity
cannot therefore be recommended (40).
A limitation of both the RDTs evaluated in this study is that
they do not differentiate between the nonfalciparum species. This
is particularly problematic given the difficulties with microscopic
diagnosis of P. knowlesi, the ring forms of which resemble those of
P. falciparum while the more mature trophozoites are indistin-
guishable from those of P. malariae. Consequently, patients with
knowlesi malaria continue to be misdiagnosed with the more be-
nign P. malariae infection, leading to inappropriate management
with potentially fatal outcomes (10). Furthermore, misdiagnosis
of P. vivax as P. knowlesi is also common (4, 10, 41), and this has
been associated with lack of antihypnozoite treatment and conse-
quent relapses from P. vivax infection (41).
An RDT that differentiates between species is therefore ur-
gently needed in areas of knowlesi malaria endemicity. P. knowlesi
has been shown to cross-react with bothP. falciparum-specific and
P. vivax-specific pLDHs (17, 18, 20, 42), and RDTs that combine
these antigens with HRP2 may allow differentiation between P.
vivax, P. falciparum, and P. knowlesi monoinfections. Prospective
evaluation of the use of these RDTs in areas of knowlesi malaria
endemicity is needed.
Our study had several limitations. Most importantly, the ma-
jority of patients were referred from district hospitals and had
already commenced malaria treatment prior to enrolment in the
study. For these patients RDTs were done on posttreatment blood
samples, possibly leading to an underestimation of sensitivity.
However, the reported sensitivities of the RDTs under these cir-
cumstances reflect the real-world utility of RDTs in referral hos-
pitals, where prior treatment is common. Moreover, we also re-
port sensitivity calculations using only patients enrolled prior to
treatment (i.e., on initial presentation to the hospital). A second
limitation was that each RDT was read by a single observer; how-
ever, regular cross-checks were performed to ensure consistent
reporting. The high sensitivity of the PfHRP2 component of both
RDTs for diagnosing P. falciparum infection also supports the
reliability of our results. Third, patients with knowlesi malaria
referred to a tertiary hospital are likely to have had higher para-
sitemias than those diagnosed in primary care settings (2), sug-
gesting that the suboptimal sensitivities of the pLDH and aldolase
RDTs found for nonsevere P. knowlesi malaria may be even lower
than reported here. Fourth, our study excluded pregnant women
and children of 12 years old; the performance of RDTs for the
diagnosis of P. knowlesi infection in these groups will need to be
evaluated in future studies. Finally, the design of our study did not
allow evaluation of the specificity of the RDTs as only patients
with PCR-confirmed malaria were enrolled; further cross-sec-
tional studies including patients with nonmalarial fevers are re-
quired to provide this information.
In conclusion, this study found that the pLDH-based First Re-
sponse RDT had high sensitivity for severe malaria from all three
Plasmodium species evaluated and that among patients with
knowlesi malaria, the intensity of the pLDH band predicted pa-
tients at risk of complications. However, neither of the RDTs had
sufficient overall sensitivity for detecting P. knowlesi. The World
Health Organization (WHO) recommends a minimum sensitivity
of 95% for P. falciparum densities of100 parasites/l (43); while
there is no recommended threshold for nonfalciparum malaria, P.
knowlesi has a 3-fold-greater likelihood of causing severe disease
(11) and fatality rates comparable to those of P. falciparum, and
hence the minimum sensitivity thresholds required for RDTs
should be at least as high for P. knowlesi as for P. falciparum.
Further studies are needed to develop reliable RDTs for the diag-
nosis of knowlesi malaria with high sensitivity and the ability to
differentiate between species.
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